Close Menu

Enzo

The company said clinical lab revenues rose 92 percent during the quarter, driven by significant volume and pricing growth due to an improved product mix.

The company said the improvements it has made to its business during the pandemic will translate to significant increases in growth once it ends.

The company said clinical services revenues rose 66 percent during the quarter, driven by significant year-over-year growth in the volume of accessions.

News items for the in vitro diagnostics industry for the week of Nov. 16, 2020.

The company said its clinical lab revenues rose nearly 5 percent, but revenues from its life sciences business fell 26 percent because of the COVID-19 pandemic.

The program is intended to help make testing for the virus more accessible to New Yorkers, the partners said.

The Enzo and Access Bio tests may be performed by any CLIA-certified high complexity lab, while use of Gene By Gene's test is limited to its developer.

News items for the in vitro diagnostics industry for the week of June 29, 2020.

The company said clinical services revenues and diagnostic testing volumes fell during the quarter due to the negative impact of the COVID-19 pandemic.

News items for the in vitro diagnostics industry for the week of March 23, 2020. 

Pages